Labcorp Declares Quarterly Dividend

BURLINGTON, N.C. , Jan. 12, 2024 /PRNewswire/ --  Labcorp  (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 13, 2024 , to stockholders of record as

Genetic Counseling: Supporting the provider and patient through the rare disease diagnostic journey

Hear from our subject matter experts about how genetic counselors can help you navigate the complex journey through rare disease, creating practice efficiencies and optimizing patient care.  

Labcorp and Hawthorne Effect Collaborate to Bring Clinical Trials Directly to Patients and Investigators in Local Communities

Collaboration Aims to Improve Patient Experience, Accessibility and Efficiency in Decentralized Clinical Trials BURLINGTON, N.C. and LAFAYETTE, Calif. , Jan. 10, 2024 /PRNewswire/ --  Labcorp , a global leader of innovative and comprehensive laboratory services, and Hawthorne Effect, Inc.

Comprehensive Profiling: Combination of Tissue and Plasma Biomarker Strategies (PMWC 2022)

Wellness solutions that improve employee health and lower costs

85% of healthcare costs stem from preventable chronic health conditions.1 Progressive companies are always looking for ways to improve employee outcomes and reduce soaring costs beyond traditional wellness programs. Our friends at Shortlister hosted Emily Roberts, executive director of client success at Labcorp, and Colin Fenn, enterprise sales leader at Labcorp, to discuss how a comprehensive suite of on-site and at-home test options, personalized one-on-one employee health coaching, an interactive online platform, and robust analytical tools support population health management strategies and empower employees to enhance their overall health. 

Getting SMARTer about New Year’s resolutions

Welcome to 2024! Many people approach the new year with excitement and anticipation for the possibilities and opportunities ahead. With the new year comes one of the most popular times and ways to make big changes in our lives—New Year’s resolutions. 

Partnering with health plans to combat kidney disease: Business solutions to report against the Kidney Health Evaluation Measure and close gaps in care

Labcorp to Speak at the 42nd Annual J.P. Morgan Healthcare Conference

BURLINGTON, N.C. , Jan. 2, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a fireside chat at the 42nd Annual J.P.

Precision Medicine World Conference (PMWC) 2024

Expanded PersistenceT™ panels for deeper analysis of CAR T persistence

Adoptive cell therapy (ACT) with T-cells reprogrammed to express chimeric antigen receptors (CAR T-cells) bind specific antigens on the surface of cancer cells and trigger a cytotoxic response. CAR T-cell therapies have been successful in patients with hematological malignancies; however, patients remain at risk of relapse due to short-term persistence or non-expansion of CAR T-cells.1,2 This requirement for persistence is more evident in solid tumors as the hostile tumor microenvironment induces T-cell exhaustion.3,4 Studies have found that genomic and phenotypic features of CAR T-cells were major determinants of their persistence. Clinical results have shown that stemness and a memory-cell-like phenotype can promote sustained in vivo persistence of adoptively transferred CAR T-cells.3,4